I9SA Stock Overview
A clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Verona Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.00 |
| 52 Week High | US$37.00 |
| 52 Week Low | US$10.20 |
| Beta | 0.44 |
| 11 Month Change | 19.72% |
| 3 Month Change | 77.08% |
| 1 Year Change | n/a |
| 33 Year Change | 683.41% |
| 5 Year Change | 776.29% |
| Change since IPO | 246.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| I9SA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 11.1% | -0.8% | 1.1% |
| 1Y | n/a | -16.7% | 12.5% |
Return vs Industry: Insufficient data to determine how I9SA performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how I9SA performed against the German Market.
Price Volatility
| I9SA volatility | |
|---|---|
| I9SA Average Weekly Movement | 13.0% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: I9SA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: I9SA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 79 | Dave Zaccardelli | www.veronapharma.com |
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company’s product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler.
Verona Pharma plc Fundamentals Summary
| I9SA fundamental statistics | |
|---|---|
| Market cap | €2.83b |
| Earnings (TTM) | -€142.38m |
| Revenue (TTM) | €5.21m |
551.5x
P/S Ratio-20.2x
P/E RatioIs I9SA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I9SA income statement (TTM) | |
|---|---|
| Revenue | US$5.62m |
| Cost of Revenue | US$543.00k |
| Gross Profit | US$5.08m |
| Other Expenses | US$158.80m |
| Earnings | -US$153.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.89 |
| Gross Margin | 90.35% |
| Net Profit Margin | -2,733.34% |
| Debt/Equity Ratio | 71.1% |
How did I9SA perform over the long term?
See historical performance and comparison